SCHEMBL22472780

SCHEMBL22472780

Cc1cc(C2CC2)n2cnc(C(=O)NC3CCC(c4ccco4)CC3)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 5/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 1/20 0.35
GLA P06280 1/20 0.35
PKM P14618 1/20 0.35
APEX1 P27695 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
MCL1 Q07820 1/20 0.35
HPGD P15428 4/20 0.35
HSD17B10 Q99714 2/20 0.35
RIPK1 Q13546 1/20 0.35
PDE4B Q07343 3/20 0.34
MAPK1 P28482 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21757774 0.84 CACNA1B (0.40) TDP1CACNA1BAPBA1ALDH1A1MEN1
SCHEMBL22472764 0.80 SCD (0.37) CACNA1BAPBA1ALDH1A1KMT2AKDM4E
SCHEMBL22767219 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL22472752 0.78 RIPK1 (0.37) ALDH1A1KMT2AKDM4ERECQLHPGD
SCHEMBL17743013 0.77 KDM4E (0.44) TDP1CACNA1BAPBA1ALDH1A1MEN1
SCHEMBL22472794 0.74 EGLN2 (0.36) RIPK1
SCHEMBL25578260 0.72 ALDH1A1 (0.56) TDP1ALDH1A1KDM4EPOLBMAPT
SCHEMBL22472806 0.72 SCD (0.38) TDP1CACNA1BAPBA1ALDH1A1KMT2A
SCHEMBL22472761 0.71 TSHR (0.36) ALDH1A1MEN1KMT2AHPGDMAPK1
SCHEMBL23901595 0.71 CRHR1 (0.38) ALDH1A1MEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215510-B1 SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2023-06-07 EP disclosed
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders GBA1, GAA, SNCA TDP1 27/4885CACNA1B 3476/4885APBA1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.